KVACW
Keen Vision Acquisition Corporation Warrant
Mentions (24Hr)
0.00% Today
Reddit Posts
Mentions
Today all the ticket for my warrants for KVACW changed to KVAWF. Must be due to the pending change to OTC? Has anybody seen this happen? Both Schwab and Fidelity show same thing.
[Keen Vision Acquisition Corporation and Medera Inc. Terminate Business Combination Agreement; Entered into a Binding Letter of Intent "to use their best efforts to negotiate and execute a replacement merger agreement (“Replacement Merger Agreement”) no later than April 10, 2026"](https://www.sec.gov/Archives/edgar/data/1889983/000121390026022404/ea0279210-8k_keen.htm) \- KVAC KVACW Bad news for KVAC and warrant holders. who have been waiting for many months: Sounds like the companies will be [throwing all of this work away](https://www.sec.gov/edgar/browse/?CIK=2037328), and *maybe* starting again with a new F-4, *maybe* by summer.
KVACW keep doing it. I know people here have a ton of these!!
Extremely high volume (300k) for KVACW, which has been stuck at <100 daily for months while awaiting further details of voting date for merger with Medera. Maybe this week will bring some news.
It's happening KVACW gang. Whisper it loudly 💖💖
Missed chance to pick more KVACW at three fiddy this morning. Sitting at 4.05 cents average
What was the target last time?? I am now empty nester with LEGATO and NETDW KVACW as my only holdings so was interested in this but 12 cents is 8 cents too much at the moment
What are the DA pops now on warrants? What is the liquidity on DA? I am in Legato and KVACW, accumulating whenever possible. Two of my larger warrant holdings
[Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation](https://www.prnewswire.com/news-releases/medera-inc-to-be-listed-on-nasdaq-through-a-merger-agreement-with-keen-vision-acquisition-corporation-302238731.html) \- KVAC KVACW
Keen Vision Acquisition ( KVAC KVACW ) "[entered into a non-binding letter of intent](https://www.sec.gov/Archives/edgar/data/1889983/000121390024025304/ea0202452-8k_keenvision.htm#:~:text=entered%20into%20a%20non%2Dbinding%20letter%20of%20intent) (the “LOI”) with a business combination target", "The Target is a clinical stage biopharmaceutical company based in Boston, U.S., focusing on i) the research, development, manufacture and use of self-developed pioneering human stem cell-based bioengineering technology platform for novel drug discovery; and ii) the development of next-generation cell and gene therapies for a range of difficult-to-treat or incurable diseases. With a pipeline of therapeutic candidates, the Target’s several experimental gene therapies have already obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (IND) approvals as ongoing clinical trials at multiple premier hospitals in the U.S. with active patient enrolments."